Ken Griffin Nurix Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,589,035 shares of NRIX stock, worth $15.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,589,035

Previous 5,800 27297.16%

Holding current value

$15.9 Million

Previous $68,000 26516.18%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$8.81 - $12.79 $2.39 Million - $3.47 Million	271,577 Added 20.61%	1,589,035 $18.1 Million
Q1 2025 May 15, 2025	BUY	$11.88 - $20.15 $5.54 Million - $9.39 Million	465,939 Added 54.72%	1,317,458 $15.7 Million
Q4 2024 Feb 14, 2025	SELL	$18.64 - $28.14 $12.7 Million - $19.1 Million	-679,686 Reduced 44.39%	851,519 $16 Million
Q3 2024 Nov 14, 2024	BUY	$18.93 - $25.69 $9.29 Million - $12.6 Million	490,539 Added 47.14%	1,531,205 $34.4 Million
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $9.93 Million - $17.6 Million	825,950 Added 384.67%	1,040,666 $21.7 Million
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $1.42 Million - $2.86 Million	182,847 Added 573.75%	214,716 $3.16 Million
Q4 2023 Feb 14, 2024	SELL	$4.25 - $10.71 $155,545 - $391,975	-36,599 Reduced 53.45%	31,869 $328,000
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $416,595 - $534,260	53,002 Added 342.7%	68,468 $538,000
Q2 2023 Aug 14, 2023	SELL	$8.7 - $13.28 $356,908 - $544,798	-41,024 Reduced 72.62%	15,466 $154,000
Q1 2023 May 15, 2023	SELL	$8.56 - $13.26 $536,857 - $831,627	-62,717 Reduced 52.61%	56,490 $501,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $14.59 $191,993 - $284,096	-19,472 Reduced 14.04%	119,207 $1.31 Million
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $1.71 Million - $2.75 Million	138,679 New	138,679 $1.81 Million
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $2.05 Million - $4.7 Million	158,504 Added 297.5%	211,783 $2.97 Million
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $210,726 - $275,068	7,973 Added 17.6%	53,279 $1.54 Million
Q3 2021 Nov 15, 2021	SELL	$22.71 - $36.69 $121,839 - $196,841	-5,365 Reduced 10.59%	45,306 $1.36 Million
Q2 2021 Aug 16, 2021	BUY	$24.21 - $35.89 $1.23 Million - $1.82 Million	50,671 New	50,671 $1.34 Million
Q1 2021 May 17, 2021	SELL	$26.98 - $50.17 $247,784 - $460,761	-9,184 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$22.85 - $48.44 $5.39 Million - $11.4 Million	-236,016 Reduced 96.25%	9,184 $302,000
Q3 2020 Nov 16, 2020	BUY	$16.05 - $34.91 $3.94 Million - $8.56 Million	245,200 New	245,200 $8.56 Million

Others Institutions Holding NRIX

# of Institutions

174

Shares Held

77.7M

Call Options Held

126K

Put Options Held

11.3K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $472M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account